Pricing a pre-revenue biotech seed round — no cash flows to discount yet, so valuation leans on team, IP, comparables, and a structured scorecard instead
A pre-seed biotech company is, in almost every financial sense, an idea wearing a lab coat. There is a founding team, a scientific thesis grounded in published biology or a proprietary early observation, and — if the team is fortunate and well-connected — a few months of proof-of-concept bench data. There is no revenue, no clinical data, frequently no filed IP, and no predictable path to cash flow for years. Standard biopharma valuation tools like discounted cash flow (DCF) or risk-adjusted net present value (rNPV) require projecting future cash flows and discounting them by stage-specific probabilities of success — but at pre-seed, there is no clinical program to assign a probability to, and no revenue line to project. Investors and founders instead have to price the company using an entirely different toolkit built for exactly this kind of extreme uncertainty.
When a biotech rNPV model is built for a Series B or M&A target (see the companion "M&A Target Valuation" simulator in this library), the core inputs are phase-specific probabilities of technical and regulatory success, peak sales estimates, and a discount rate applied to projected future cash flows. Every one of those inputs requires the company to already have a clinical or at least a well-characterized preclinical program with comparable precedent data.
At true pre-seed, none of that exists. The "asset" being valued is often just: a founding team's domain expertise, a scientific rationale (frequently derived from an academic lab or postdoc project), maybe a handful of in vitro or animal data points that are directionally encouraging but far from being statistically powered studies, and a rough sense of the market the resulting product might eventually address. Trying to force a DCF onto this produces a number that looks precise but is actually almost entirely noise — the output is dominated by whatever peak-sales and probability-of-success assumptions the modeler chose, none of which are grounded in company-specific evidence yet.
A DCF model run on a pre-seed biotech is not "wrong" in the sense of a calculation error — it is wrong in the sense that its precision is fake. The inputs are guesses about a company that has not yet generated the data needed to constrain those guesses.
A software seed round can sometimes be priced on a founder's laptop and a few thousand dollars of cloud spend before the first paying customer. Biotech seed rounds are structurally different, and larger, because getting from "thesis" to "de-risking data" requires real capital before any product-market signal is even possible:
• Wet-lab infrastructure: reagents, cell lines, animal studies, and CRO (contract research organization) fees for even minimal proof-of-concept work routinely run into the hundreds of thousands of dollars • Specialized personnel: a computational biologist or synthetic chemist commands a materially different salary than an early software engineer, and biotech teams often need several specialists simultaneously (chemistry, biology, regulatory) rather than one generalist • Regulatory and IP costs: provisional and non-provisional patent filings, freedom-to-operate searches, and early regulatory consultation are effectively fixed costs that must be paid regardless of company size • Longer runway requirements: a biotech seed round typically needs to fund 18–30 months of research to reach the next credible value-inflection milestone (e.g., a lead candidate, an IND-enabling data package), versus 12–18 months for a typical software seed round to reach initial product-market fit signal
This is why a biotech seed round of $2–5M is common where a comparable-stage software seed round might be $500K–$1.5M — the underlying capital intensity of generating the next piece of de-risking evidence is simply higher.
In the absence of cash-flow-based valuation tools, seed-stage biotech investors are effectively underwriting three things: the team's ability to execute (do they have the specific technical and translational expertise this program requires, and have they operated in resource-constrained environments before), the defensibility of the scientific thesis (is there a real, differentiated mechanism or platform advantage, or is this a "me-too" approach that a well-funded incumbent could replicate quickly), and the size and structure of the eventual opportunity if the science works (is this a niche indication with a clear regulatory and reimbursement path, or a large market with correspondingly larger clinical and commercial risk).
These three questions — team, science, market — are precisely the inputs that feed into the structured scorecard method covered in the next stage. The scorecard does not replace judgment; it is a discipline for making that judgment explicit, comparable across deals, and less vulnerable to being swayed by whichever factor the investor happens to weight most heavily in the room.
The Scorecard Valuation Method (sometimes called the Bill Payne method, and closely related to Dave Berkus's simpler five-factor approach) was originally built for early-stage tech investing, where — just as in pre-seed biotech — there is no revenue or cash flow history to anchor a valuation. The method starts from a regional benchmark pre-money valuation for comparable-stage deals, then adjusts that benchmark up or down based on how the specific company compares to typical deals across a fixed set of weighted factors.
A generic tech-VC scorecard typically weights management team most heavily (often 25–30%), followed by market size, product/technology, competitive environment, and a handful of smaller factors like marketing/sales channels and need for additional financing. Biotech investors adapt this framework by relabeling and reweighting factors to match what actually predicts biotech seed-stage outcomes:
• Team (typically ~28%): scientific founder credibility, prior translational or company-building experience, completeness of the founding team (is there someone who can actually run a GLP-compliant study, not just publish a paper about the biology) • Market Size (~22%): total addressable patient population, pricing precedent in the therapeutic area, payer/reimbursement dynamics • Technology / IP (~20%): defensibility of the core mechanism, freedom-to-operate, platform vs. single-asset breadth • Competitive Landscape (~12%): number and stage of competing programs, incumbent advantage, differentiation clarity • Partnership Need (~8%): does this program realistically require a pharma partner to reach the clinic, and how does that affect capital efficiency • Validation Stage (~10%): how much of the thesis is backed by data already in hand versus still purely theoretical
Each factor is scored relative to a "typical" deal (1.0×) — a factor scored 1.3× means the company is judged meaningfully stronger than the median comparable-stage deal on that dimension; 0.7× means meaningfully weaker.
The mechanics are a weighted sum: multiply each factor's score by its weight, sum across all factors to get a single composite multiplier, then apply that multiplier to the regional benchmark pre-money valuation for comparable-stage deals.
Valuation = Benchmark Pre-Money × Σ(Factor Weight × Factor Score)
If the regional benchmark for pre-seed biotech is $8.5M and a company scores strongly across team and technology but averages on market size and competition, its composite multiplier might land around 1.1–1.3×, producing an adjusted valuation in the $9–11M range. A first-time founding team with an unproven thesis and a crowded competitive field might score a composite multiplier closer to 0.6–0.8×, pulling the valuation down toward $5–7M.
The scorecard method's real value is not mathematical precision — it is forcing every party in the negotiation to itemize which specific factors they are pricing in or out, turning an otherwise vague "gut feel" negotiation into a structured, revisitable disagreement about specific, named inputs.
The scorecard method inherits a structural weakness from its inputs: the regional benchmark pre-money figure and the "typical deal" baseline that factor scores are compared against are themselves derived from recent comparable transactions — meaning the method is fundamentally a structured way of anchoring to the comparables market (covered next), not an independent, first-principles valuation. It also compresses genuinely different kinds of uncertainty (technical risk, market risk, execution risk) into a single multiplicative score, which can understate tail risk in either direction — a company can score well on every individual factor and still fail for a reason the scorecard was never designed to capture, like an unexpected competitive entrant or a shift in regulatory guidance for the target indication.
| Product | Indication | Trial Design | Key Result |
|---|---|---|---|
| Team | 25–30% | Founder/scientific credibility, execution track record | Highest-weighted, hardest to fake |
| Market Size | 20–24% | TAM, pricing precedent, payer dynamics | Anchors upside ceiling |
| Technology / IP | 18–22% | Mechanism defensibility, freedom-to-operate | Drives long-term moat |
| Competition | 10–14% | Competing program count and stage | Signals differentiation urgency |
| Partnership Need + Validation | 16–20% | Capital efficiency, data already in hand | Tempers pure narrative risk |
A scorecard output is only useful if it roughly agrees with what the market is actually paying for similar companies right now. Comparable-deal benchmarking surveys recent seed-stage biotech financings — grouped by modality (small molecule, biologics, cell & gene therapy, platform/AI-driven discovery, diagnostics) and indication — to sanity-check the scorecard estimate against observed, real transaction pricing.
It is tempting to think comparable-deal analysis is redundant with the scorecard method, since the scorecard already starts from a regional benchmark pre-money figure. In practice the two serve different purposes: the scorecard's benchmark is typically a broad, blended median across many biotech seed deals regardless of modality, while a proper comparables analysis narrows the reference set to companies that actually resemble the target on the dimensions that most affect biotech pricing specifically — modality (cell & gene therapy programs have historically commanded a premium over small-molecule programs at seed stage, reflecting both higher perceived platform value and higher capital requirements), indication (rare disease and oncology programs price differently than broader chronic-disease programs), and vintage (biotech seed pricing moves with the broader venture funding cycle, sometimes swinging 20–30% across 18-month windows as capital availability shifts).
Running the scorecard-derived estimate through a comparables lens either confirms the estimate is reasonable, or flags that the scorecard has drifted from what the market will actually bear — which happens more often than either method alone would suggest, because scorecard factor scoring is itself subjective and can drift optimistic during hot funding cycles.
A useful comparable set for a seed-stage biotech benchmarking exercise typically requires:
• Modality match: comparing a cell & gene therapy seed round against a small-molecule seed round produces a misleading benchmark, because the two carry fundamentally different capital requirements and platform-value narratives • Stage match: seed-stage comparables should be pre-Series-A companies with comparable data maturity — mixing in Series A rounds (which typically have more de-risking data and correspondingly higher, less comparable valuations) skews the reference set upward • Recency: biotech seed pricing is cyclical with the broader venture funding environment; comparables older than 12–18 months can be meaningfully stale, particularly during periods of rapid funding-environment change • Sample size discipline: a comparable set of 2–3 deals is not a benchmark, it is an anecdote; useful comparable analysis generally wants at least 8–10 data points per modality/indication bucket to say anything statistically defensible about central tendency and spread
Comparable-deal data at seed stage is notoriously noisy and often not fully public — actual valuation terms are frequently withheld or only partially disclosed, so practitioners triangulate from press releases, SEC filings where applicable, industry surveys, and informal investor networks rather than a single clean dataset.
When the scorecard-adjusted valuation and the comparable-deal range diverge meaningfully, the disagreement itself is informative. A scorecard estimate that runs well above the comparable range often means factor scoring was too generous — commonly on team or technology, the two most subjective factors. A scorecard estimate that runs below the comparable range can mean the scorecard's underlying regional benchmark is stale, or that the comparable set has been inflated by a small number of unusually hot deals in a narrow sub-sector that do not represent the broader market.
In practice, sophisticated seed-stage negotiations treat the scorecard output as a starting anchor and the comparable range as a validity check, then negotiate the final number within whatever overlap exists between the two — with the specific point within that overlap typically settled by relative negotiating leverage (how much competing investor interest exists, how much runway the company has before it needs to close) rather than by further refining either model.
Agreeing on a valuation number is only half the negotiation — the round also has to be structured through a specific legal instrument, and the choice between a SAFE, a convertible note, and a priced equity round changes both the mechanics of how that valuation converts into ownership and, often, the effective price paid once conversion actually happens.
A SAFE is not debt and not equity at signing — it is a contractual right to receive equity in a future priced round, typically the company's Series A. Its two key economic terms are a valuation cap (the maximum pre-money valuation at which the SAFE converts, protecting the early investor from being diluted at a much higher future price) and, in some versions, a discount rate (giving the SAFE holder shares at a discount to whatever price new investors pay in that future round). No interest accrues, and there is no maturity date forcing repayment — if the company never raises a priced round, the SAFE simply never converts, which is part of why SAFEs are popular for fast, low-legal-cost seed closings, but also why they can leave cap table uncertainty unresolved for longer than founders sometimes expect.
A convertible note is legally debt: it accrues interest (commonly 4–8% annually) and technically has a maturity date, at which point, if the company has not raised a qualifying priced round, the note technically becomes due and payable — though in practice maturity dates on seed-stage biotech notes are frequently extended or renegotiated rather than triggering actual repayment, since most seed-stage biotechs do not have the cash to repay. Notes typically carry the same valuation-cap and discount mechanics as a SAFE, but the accruing interest means the effective number of shares a note holder receives at conversion is slightly larger than the same-sized SAFE investment, all else equal — because the interest amount also converts into equity.
A priced equity round sets a fixed pre-money valuation at the time of the round itself, and investors receive their ownership percentage immediately at close rather than waiting for a future conversion event. This removes the valuation-cap/discount uncertainty entirely but requires the company and investors to agree on an actual, binding valuation number today — precisely the number the scorecard and comparables analysis in the earlier stages exist to help negotiate. Priced rounds also carry meaningfully higher legal costs and longer closing timelines than a SAFE or note, since they require a full set of definitive equity documents (charter amendments, voting agreements, protective provisions) rather than the comparatively lightweight SAFE/note templates.
The practical effect on founder dilution differs across the three instruments even at an identical headline valuation: because SAFEs and notes typically convert at a discount to the next round's price (via the cap or discount mechanic), the effective price per share the early investor ultimately pays is usually lower than the headline valuation implies — meaning SAFE and note investors often end up with more ownership per dollar invested than a priced-round investor writing the same check at the same headline number, all else equal.
The choice of instrument is not just a legal formality — a low valuation cap on a SAFE can end up transferring more ownership to seed investors than a founder intended, especially if the next priced round happens at a valuation far above the cap, since conversion locks in the cap price rather than the (higher) actual round price.
| Product | Indication | Trial Design | Key Result |
|---|---|---|---|
| SAFE | Valuation cap + optional discount | No interest, no maturity, converts at next priced round | Fastest, cheapest to close |
| Convertible Note | Cap + discount + interest | Technically debt; maturity date often extended | Familiar structure to traditional investors |
| Priced Equity | Fixed pre-money valuation | Immediate ownership %, full equity docs | No conversion uncertainty later |
Every input from the previous four stages — the scorecard-adjusted estimate, the comparable-deal range, and the chosen instrument's conversion mechanics — funnels into a final negotiation between investor and founder positions that converges on three linked numbers: the pre-money valuation, the total round size, and the resulting post-money ownership split between founders, new investors, and any option pool carved out for future hires.
Once a pre-money valuation is agreed — informed by the scorecard estimate, sanity-checked against comparables, and adjusted for whatever instrument-specific mechanics apply — the remaining negotiation is comparatively mechanical:
Post-Money Valuation = Pre-Money Valuation + Round Size
New Investor Ownership % = Round Size ÷ Post-Money Valuation
For example, an $8M pre-money valuation with a $3M round size produces an $11M post-money valuation, and new investors own 3/11 ≈ 27% of the company at close. Increasing the round size while holding pre-money fixed mechanically increases new-investor ownership and dilutes existing holders proportionally more — which is exactly why round size itself is a negotiated variable, not just a function of "however much the company wants to raise": every additional dollar raised at a fixed pre-money valuation costs the founders and any existing option pool the same percentage-of-company price.
Most priced seed rounds require the company to carve out or top up an employee option pool (commonly 10–15% of the post-money cap table) to have equity available for future hires — and by convention, that pool is typically created out of the pre-money share count, meaning its dilutive cost falls almost entirely on existing shareholders (founders and any earlier SAFE/note holders converting in the same round) rather than being shared proportionally with the new investors coming in at this round.
This mechanic, sometimes called the "option pool shuffle," means a headline pre-money valuation can be economically less favorable to founders than it first appears once the pool carve-out is accounted for — a $10M pre-money valuation with a 15% option pool created pre-money is effectively closer to an $8.5M pre-money valuation for the founders' actual retained ownership math. Sophisticated founders negotiate not just the headline valuation number but explicitly where in the cap table structure the option pool gets created.
Two term sheets with an identical headline pre-money valuation can produce meaningfully different founder ownership outcomes depending on option pool size and placement — the number on the term sheet's first line is never the whole story.
Reaching agreement on pre-money valuation, round size, and pool structure produces a term sheet — a non-binding (for most terms) document that captures the economic and governance terms both sides intend to finalize. From there, the round proceeds to definitive documentation (for priced rounds: charter amendments, stock purchase agreements, voting and investor rights agreements; for SAFEs/notes: the standardized instrument itself plus a side letter for any negotiated pro-rata or information rights), due diligence on IP and any existing agreements, and finally closing, at which point capital is wired and the new post-money cap table becomes effective.
For a pre-revenue biotech, this entire process — from first scorecard conversation to closed round — commonly takes 2–5 months, materially longer than the fastest tech seed closings, reflecting both the more complex diligence (IP freedom-to-operate, scientific advisory input) and the larger, more capital-intensive round sizes typical of the sector.